Optimization and Application of HPV-16 HUZIDOS

Oct. 16, 2018

Optimization and Application of HPV-16 HUZIDOS

Technology description

This article
The present invention relates to the use of two ideal plasmid DNA constructions, one containing an expression gene fused with herpes simplex virus type 1 glycoprotein D (9D) human papillomavirus E7 oncoprotein (HPV-16) and the other containing a gene expressing interleukin-2 (IL-2), for the preparation of pharmaceutical compositions and experimental studies of pharmaceutical compositions and their use in tumor control induced by HPV-16. Such pharmaceutical compositions interest the pharmaceutical industry in the manufacture of human drugs for the control of tumors.
The management of this pharmaceutical composition, in animals previously challenged by TC-1 tumor cell lines, provides overall protection for tumor development (100%), both prophylactically and therapeutically, an unprecedented strategy requiring invention protection aimed at future clinical applications in humans and animals.
Development Plan Field: Health and Personal Care 0041/2009 FMR PPolo Black Belan
Support and support: FAPESP
Case No. 2008/11658-9, Foundation for the Investigation and Protection of the State of S ã o Paulo (FAPESP). "The opinions, assumptions and conclusions presented in this material are the responsibility of the author and do not necessarily reflect the views of FAPESP."

Advantages

It can be used in drugs designed to control tumors. The target audience is companies active in the pharmaceutical sector.

Figure: Therapeutic protection trial of CS7BL/6 mice stimulated by TC-1 tumor cells. Animals were immunized with a dose of plL-2 or pVangE7 vector or with a dose of a pharmaceutical composition containing pVangE7 and plL-2 vector at a dose of 50 pg DNA/go. Vaccines and pharmaceutical compositions were administered 3 days after challenge.